Back to Search
STANLEY LIPKOWITZ, MD, PHD
MD, PHD
Medical Oncology Physician
NPI: 1255317657Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D0035478(MD)
Research & Publications (20)
PPARgamma agonists follow an unknown TRAIL in lung cancer.
PMID 17224637·Cancer Biol Ther·2007
8-other
The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer.
PMID 12559039·Breast Cancer Res·2003
6-review
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.
PMID 18266105·Breast Cancer Res Treat·2009
8-other
2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts.
PMID 19050321·Reprod Sci·2008
8-other
TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.
PMID 17136491·Apoptosis·2007
8-other
Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b.
PMID 17679095·Mol Cell·2007
8-other
EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.
PMID 16702950·Oncogene·2006
7-preclinical
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
PMID 16407879·Nat Clin Pract Oncol·2006
5-case
Regulating the regulator: negative regulation of Cbl ubiquitin ligases.
PMID 16406635·Trends Biochem Sci·2006
6-review
Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.
PMID 15908654·J Clin Oncol·2005
3-trial
Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl).
PMID 15315962·Blood·2005
7-preclinical
A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
PMID 15123609·J Biol Chem·2004
7-preclinical
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
PMID 15284258·J Clin Oncol·2004
8-other
Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b.
PMID 15273720·Oncogene·2004
8-other
Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.
PMID 15093541·Cancer Cell·2004
7-preclinical
N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.
PMID 14765134·Cell Death Differ·2004
8-other
WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation.
PMID 12907674·J Biol Chem·2003
8-other
Cbl-3-deficient mice exhibit normal epithelial development.
PMID 14560016·Mol Cell Biol·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- NATIONAL NAVAL MEDICAL CENTER, 8901 WISCONSIN AVENUE
BETHESDA, MD 20889 - Phone
- (301) 295-6230
Quick Facts
- NPI
- 1255317657
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile